Status:
UNKNOWN
Pergolide for Cognitive Symptoms in Schizotypal Personality Disorder
Lead Sponsor:
Bronx VA Medical Center
Conditions:
Schizotypal Personality Disorder
Other Personality Disorders
Eligibility:
All Genders
18-60 years
Phase:
NA
Brief Summary
Hypothesis: Schizotypal personality disorder patients will show cognitive improvements in 1) working memory 2) learning and memory 3) sustained attention 4) enhanced performance on the AX-CPT, N-back ...
Eligibility Criteria
Inclusion
- DSM-IV criteria for Schizotypal Personality Disorder (or meets full criteria bar one) or another personality disorder and shows impairment on markers of cognitive functioning. Medically healthy, not abusing drugs or alcohol, is at least two weeks medication-free and does not have significant neurological disease.
- \-
Exclusion
- DSM-IV or RDC criteria for Schizophrenia or any Schizophrenia-related psychotic disorder or for Bipolar Disorder. Any other Axis I disorders must be transient and preceded by the personality disorder diagnosis, which should be primarily responsible for subject's functional impairment.
- \-
Key Trial Info
Start Date :
October 1 2000
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00252044
Start Date
October 1 2000
Last Update
November 21 2005
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mount Sinai School of Medicine
New York, New York, United States, 10029